Obesity Medicine

Latest News

Investigational Oral GLP-1 RA, Orforglipron, Yields Dose-Dependent Weight Loss in Phase 3 Trial
Investigational Oral GLP-1 RA, Orforglipron, Yields Dose-Dependent Weight Loss in Phase 3 Trial

September 17th 2025

EASD 2025. A new oral GLP-1 receptor agonist, orforglipron, shows promise for significant weight loss and improved cardiometabolic health in adults with obesity.

nt Semaglutide Quells "Food Noise" Among Adults on Treatment for Obesity and Overweight / image credit freshidea/stock.adobe.com
Semaglutide Quells "Food Noise," Improves Mental Health Among Adults on Treatment for Obesity and Overweight

September 17th 2025

Amylin Injectable Cagrilintide Demonstrates Weight Loss of 11.8% in Late-Stage Trial: Novo Nordisk Update / image credit Timothy Garvey, MD courtesy of University of Alabama at Birmingham
Amylin Injectable Cagrilintide Demonstrates Weight Loss of 11.8% in Late-Stage Trial: Novo Nordisk Update

September 16th 2025

Pharmacy-Based FIT Distribution May Expand CRC Screening: Daily Dose / image credit: ©New Africa/AdobeStock
First Generic GLP-1 RA Approved for Weight Management in the US: Daily Dose

September 10th 2025

Real-World Study: Semaglutide Lowers Cardiovascular Risk More Than Tirzepatide in Adults With Obesity and CVD / Image credit: ©Corona Borealis/AdobeStock
Real-World Study: Semaglutide Lowers Cardiovascular Risk More Than Tirzepatide in Adults With Obesity and CVD

September 2nd 2025

More News

© 2025 MJH Life Sciences

All rights reserved.